Anti-Hypertensive Drugs - Europe

Europe

The Anti-Hypertensive Drugs market in Europe is expected to witness a significant increase in revenue, reaching €3.60bn in 2024.
Moreover, the market is projected to exhibit a compound annual growth rate (CAGR) of 0.00% between 2024 and 2029, leading to a market volume of €3.60bn by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue in this market, amounting to €11,400.00m in 2024.
In Europe, Germany is leading the way in the development and adoption of innovative anti-hypertensive drugs.

Key regions: Japan, India, Italy, Brazil, South Korea

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The market for Anti-Hypertensive Drugs in Europe has been steadily growing over the years.

Customer preferences: The primary customer preference in the Anti-Hypertensive Drugs market in Europe is for drugs that are effective and have minimal side effects. Customers also prefer drugs that are affordable and easily accessible.

Trends in the market: One of the major trends in the Anti-Hypertensive Drugs market in Europe is the increasing use of combination therapy. This involves the use of two or more drugs to manage hypertension. Combination therapy is becoming popular among physicians as it allows for better blood pressure control and reduces the risk of side effects. Another trend in the market is the increasing use of generic drugs. The use of generic drugs is driven by the need to reduce healthcare costs.

Local special circumstances: In countries such as Germany and the UK, there is a growing trend towards self-monitoring of blood pressure by patients. This is driven by the increasing availability of blood pressure monitors and the need for patients to take an active role in managing their health. In Spain, there is a growing demand for natural and herbal remedies for hypertension. This is driven by the cultural preference for natural remedies and the belief that they are safer than conventional drugs.

Underlying macroeconomic factors: The Anti-Hypertensive Drugs market in Europe is driven by several macroeconomic factors. One of the key factors is the aging population in Europe. Hypertension is more common in older adults, and as the population ages, the demand for Anti-Hypertensive Drugs is expected to increase. Another factor is the high prevalence of hypertension in Europe. According to the European Society of Cardiology, hypertension affects around one-third of the adult population in Europe. This high prevalence is driving the demand for Anti-Hypertensive Drugs. Additionally, the increasing focus on preventive healthcare and the need to reduce healthcare costs are also contributing to the growth of the Anti-Hypertensive Drugs market in Europe.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.